Accelerating DHT Research and Drug Development with Open-Source Big Data from Population Studies

Immunotherapy treatments such as CAR‑T and T‑cell engagers (TcEs) are transforming patient care across oncology and immunology indications, with growing experience demonstrating that adverse events such as cytokine release syndrome (CRS) can be effectively monitored and managed following infusion. However, variability in monitoring approaches, inconsistent data collection, and limited standardization across care sites continue to drive conservative, resource‑intensive inpatient care models that restrict broader adoption and outpatient delivery of these life‑changing therapies. 

During this session, a multidisciplinary panel of speakers from Boehringer Ingelheim, the Digital Medicine (DiMe) Society, Mayo Clinic, and Ametris will examine how fit-for-purpose digital health technologies and more standardized and precise clinical data collection can enable a more continuous, objective view of the patient experience, supporting earlier detection of change, greater confidence in care decisions, and more scalable treatment models beyond the hospital. Together, these advances have the potential to expand patient access to immunotherapy treatments like CAR-Ts and TcEs through outpatient care and care in community settings. 

Finally, we will introduce the DECODE CRS Coalition and discuss why this type of collaborative, precompetitive approach is needed to advance system-wide solutions that enable safer outpatient care, broader access to immunotherapies, and improved patient outcomes across diverse real-world settings.

Key discussion topics include:

• Immunotherapy context and CRS: Overview of immunotherapy treatments and CRS as a common, generally manageable adverse event that remains operationally complex

• How adverse events limit access: The impact of monitoring requirements, inpatient defaults, geographic constraints, and risk-averse care models on patient access

• Variability in monitoring and treatment: Differences across sites, therapies, and trials, including inconsistent monitoring approaches and interpretation of grading criteria

• Why standardized data is critical: The need for consistent, comparable data to enable evidence-based protocols and increase confidence in expanding care beyond specialized centers

• Role of wearable DHTs: How continuous, objective physiologic monitoring can support earlier detection, safer outpatient pathways, and more scalable, standardized models of care

• DECODE CRS Coalition: Research goals, workstreams, and current progress of this new collaborative, precompetitive coalition to address this industry-wide barrier and expand access to immunotherapy.

Speakers